Propanc Biopharma (PPCB) Research & Development (2010 - 2025)
Propanc Biopharma (PPCB) posted quarterly Research & Development of $19961.0 for Q4 2025, down 63.3% year-over-year from $54388.0 in Q4 2024, and down 66.84% quarter-over-quarter from $60201.0 in Q3 2025.
Propanc Biopharma (PPCB) Research & Development (2010 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Research & Development for 16 consecutive years, with $19961.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Research & Development fell 63.3% year-over-year to $19961.0; the TTM figure through Dec 2025 stood at $187781.0 (down 19.73% YoY), while the FY2025 annual figure was $223721.0, down 9.83% from the prior year.
- Research & Development declined to $19961.0 in Q4 2025 per PPCB's latest filing, from $60201.0 in the prior quarter.
- Across five years, Research & Development topped out at $114022.0 in Q4 2023 and bottomed at $5696.0 in Q2 2023.
- Historically, Research & Development has averaged $59295.0 across 5 years, with a median of $54242.5 in 2024.
- Annual changes were most pronounced in 2023 — Research & Development slumped 94.74% — and 2024, when it jumped 819.77%.
- Propanc Biopharma's Research & Development stood at $50753.0 in 2021, then soared by 47.53% to $74878.0 in 2022, then surged by 52.28% to $114022.0 in 2023, then slumped by 52.3% to $54388.0 in 2024, then tumbled by 63.3% to $19961.0 in 2025.
- Business Quant data shows PPCB's Research & Development at $19961.0 in Q4 2025, $60201.0 in Q3 2025, and $53522.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | 19,961.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 19,961.00 |
| Sep 30, 2025 | 60,201.00 |
| Jun 30, 2025 | 53,522.00 |
| Mar 31, 2025 | 54,097.00 |
| Dec 31, 2024 | 54,388.00 |
| Sep 30, 2024 | 61,714.00 |
| Jun 30, 2024 | 52,390.00 |
| Mar 31, 2024 | 65,448.00 |
| Dec 31, 2023 | 114,022.00 |
| Sep 30, 2023 | 16,242.00 |
| Jun 30, 2023 | 5,696.00 |
| Mar 31, 2023 | 66,020.00 |
| Dec 31, 2022 | 74,878.00 |
| Sep 30, 2022 | 101,325.00 |
| Jun 30, 2022 | 108,350.00 |
| Mar 31, 2022 | 50,395.00 |
| Dec 31, 2021 | 50,753.00 |
| Sep 30, 2021 | 46,554.00 |
| Jun 30, 2021 | 85,058.00 |
| Mar 31, 2021 | 44,887.00 |